drugset / Trial / NCT00251992

Nexium Dyspepsia/AST

NCT00251992

Phase 3 Completed 1200 enrolled AstraZeneca
RandomizedParallel-groupDouble-blindTreatment

Summary

The aim is to evaluate if the resolution of upper abdominal symptoms (pain or burning) during an acid suppressive test trial of esomprazole given daily for 7 days predicts symptoms resolution at the end of a subsequent treatment period of 7 weeks.

Timeline

Start
2002-12
Primary completion
2005-01
Completion
2005-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Esomeprazole Small molecule 40 mg

Indications